Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)
Inhibikase Therapeutics (IKT) reported Short term Debt of $37944.0 for Q2 2025, down 75.07% year-over-year from $152224.0 in Q2 2024, and down 49.25% quarter-over-quarter from $74772.0 in Q1 2025.
Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of Short term Debt data on file, last reported at $37944.0 in Q2 2025.
- Short term Debt for Q2 2025 came in at $37944.0, down 75.07% year-over-year; the trailing twelve-month figure through Jun 2025 was $37944.0 (down 75.07% YoY), and the FY2024 annual result was $110517.0, down 26.37% from the prior year.
- Short term Debt eased to $37944.0 in Q2 2025 per IKT's latest filing, from $74772.0 in the prior quarter.
- Over five years, Short term Debt peaked at $152224.0 in Q2 2024 and troughed at $37944.0 in Q2 2025.
- A 4-year average of $129475.2 and a median of $146368.5 in 2022 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2023 and 2025: Short term Debt climbed 4.92% in 2023, then tumbled 75.07% in 2025.
- A 4-year view of Short term Debt shows it stood at $145836.0 in 2022, then climbed by 2.92% to $150095.0 in 2023, then fell by 26.37% to $110517.0 in 2024, then tumbled by 65.67% to $37944.0 in 2025.
- Business Quant data shows IKT's Short term Debt at $37944.0 in Q2 2025, $74772.0 in Q1 2025, and $110517.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 37,944.00 |
| Mar 31, 2025 | 74,772.00 |
| Dec 31, 2024 | 110,517.00 |
| Sep 30, 2024 | 145,210.00 |
| Jun 30, 2024 | 152,224.00 |
| Mar 31, 2024 | 151,159.00 |
| Dec 31, 2023 | 150,095.00 |
| Sep 30, 2023 | 149,030.00 |
| Jun 30, 2023 | 147,966.00 |
| Mar 31, 2023 | 146,901.00 |
| Dec 31, 2022 | 145,836.00 |
| Sep 30, 2022 | 142,048.00 |